Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Liver Fibroses, Cirrhosis
Interventions: Atorvastatin 20mg, Placebo; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CTLA4-IgG4m (RG2077), Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Chula Vista, California • Fort Myers, Florida • Orlando, Florida

Conditions: Varicella
Interventions: VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Months to 23 Months
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Sexual Wellness, Women Health
Interventions: Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
Interventions: Placebo, JNJ-42160443; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Glendora, California + 17 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with HCL or PLGS; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 65 Years and older
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Orlando, Florida • Rochester, Minnesota • Syracuse, New York + 1 more

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: MTX-474, Placebo; Biological · Other
Lead sponsor: Mediar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more

Conditions: Low Back Pain
Interventions: Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo; Drug
Lead sponsor: MEDRx USA, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Carlsbad, California • Miami, Florida • New York, New York + 4 more

Conditions: Type 2 Diabetes Mellitus
Interventions: rosiglitazone, metformin, PN2034; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 21 Years to 72 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more

Conditions: Urinary Incontinence
Interventions: PureWick System, UltraFlex Self-Adhering Male External Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Dyslipidemia
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 14
States / cities: Huntsville, Alabama • Lincoln, California • Palm Springs, California + 11 more

Conditions: Primary Biliary Cholangitis
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 10
States / cities: Coronado, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Eosinophilic Asthma
Interventions: KT-621, Placebo; Drug · Other
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 34
States / cities: Lancaster, California • Long Beach, California • Northridge, California + 28 more

Conditions: Alzheimer Disease
Interventions: DMXB-A; Drug
Lead sponsor: CoMentis; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: 280 South San Francisco, California

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 9
States / cities: Culver City, California • Glendale, California • Miami, Florida + 4 more

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glendale, Arizona

Conditions: Stress Urinary Incontinence
Interventions: Vaginal pessary; Device
Lead sponsor: Liv Labs Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Lake Forest, Illinois • Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: Hybrid Closed Loop (HCL), Control-IQ with MyTDI; Device
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 18 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Thermal Burns
Interventions: NexoBrid, Standard of Care (SOC), Gel Vehicle; Drug · Procedure
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 18
States / cities: Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more

Conditions: Healthy Participants
Interventions: TAK-510, TAK-510 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Faricimab, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 85
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more

Search by objective public record fields.

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

Pippa Pessary Study (Clinical Trial)

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

A Study of TAK-510 in Healthy Adults

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)